Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.

The median iDFS was longer for patients in Arm C compared to Arms A and B, with a 2-year iDFS in Arm C of 91% compared to 47% in Arm A or 53% in Arm B, although the difference did not reach statistical significance (Fig. 2a and Supplementary Table 6 ).

also in 111,027 other papers